Key Takeaways
Cencora Inc. (COR) reported second-quarter earnings that fell short of analyst estimates, adding pressure to a stock that has underperformed the broader market this year.
The pharmaceutical distributor announced quarterly earnings of $4.75 per share, missing the Zacks Consensus Estimate of $4.80. The result was an increase of 7.5 percent from the $4.42 per share reported in the same quarter a year ago.
Revenue for the quarter also missed analyst expectations of $80.76 billion, according to a company announcement, though a final figure was not released. The results were impacted by the loss of a large oncology customer and a previously off-boarded grocery client, which created modest headwinds against top-line growth.
The miss overshadowed continued strength in Cencora's U.S. Healthcare Solutions segment, which remains its primary growth driver. The company saw resilient demand for specialty pharmaceuticals, including strong volumes of GLP-1 drugs, and benefits from the integration of its acquisitions of Retina Consultants of America and OneOncology. While the core U.S. distribution business performed well, the International Healthcare Solutions segment faced pressure from pricing dynamics in some European markets.
The earnings miss is likely to weigh on shares, which have already declined 10.1 percent year-to-date, compared to a 6.4 percent gain in the S&P 500. Investors will be watching for management's updated full-year guidance to assess the impact of customer losses and international pressures on Cencora's future profitability.
This article is for informational purposes only and does not constitute investment advice.
